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Abstract 
Background 
Regional anaesthesia improves short-term blood flow through arteriovenous fistulae (AVF). 
We previously demonstrated that regional anaesthesia (RA) compared to local anaesthesia 
(LA) improves primary AVF patency at three months. In this study, we report the effects of 
anaesthesia on longer-term AVF patency with corresponding cost-benefit analysis. 
Methods 
We performed an observer-blinded randomised controlled trial at three university hospitals 
in Glasgow, UK. 126 patients undergoing primary radiocephalic or brachiocephalic AVF 
creation were randomised to receive RA (brachial plexus block; 0·5% L-bupivacaine and 
1·5% lidocaine with epinephrine) or LA (0·5% L-bupivacaine and 1% lidocaine). Primary 
outcome measures have previously been reported. Primary, functional, and secondary 
patency at one year, re-interventions, and additional access procedures are reported here. 
Data were analysed by intention-to-treat. Cost effectiveness analyses were performed. The 
study was registered with ClinicalTrials.gov (NCT01706354).  
Results 
At 12 months, both primary patency (50 [79%] vs 37 patients [59%]; OR 2·7 [95% CI 1·6, 3·8], 
P=0·02) and functional patency (43 [68%] vs 31 patients [49%]; OR 2·1, [95% CI 1·5, 2·7] 
P=0·008) were higher in the RA cohort. 21 revisional procedures, 53 new AVFs, and 50 TDCs 
were required in 12 months. RA resulted in net savings of £195·10/patient at one year, and 
an ICER of approximately £12,900 per QALY over a five-year time horizon. Results were 
robust following extensive sensitivity and scenario analyses. 
Conclusions 
Compared to LA, RA significantly improved both primary and functional AVF patency at one 
year and is cost-effective. 
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Introduction 
 
Arteriovenous fistulae (AVF) are the haemodialysis (HD) access modality of choice for 
patients with end stage renal disease (ESRD)1 and are associated with lower rates of 
systemic sepsis and mortality compared to other vascular access options.2,3 However, the 
early failure rate is approximately 30%4-8 and is influenced by pre-operative vessel size, 
arterial inflow and early post-operative blood flow, all of which can be affected by 
anaesthetic technique.9,10 
 
Regional anaesthesia (RA), such as brachial plexus block (BPB), involves targeted injection of 
local anaesthetic (LA) to block motor and sensory nerves supplying the operative site. Unlike 
LA infiltration for AVF creation, RA also blocks sympathetic nerves resulting in vasodilation, 
improved blood flow and reduced vasospasm both perioperatively and in the early 
postoperative period.10,11,12,13 Until recently, there was no evidence that short-term 
perioperative haemodynamic changes secondary to anaesthesia could improve longer-term 
fistula patency.11,14 
 
We previously demonstrated that medium-term (three month) primary AVF patency rates 
were higher in patients randomised to RA compared to LA infiltration at the time of 
radiocephalic (RCF) or brachiocephalic (BCF) fistula creation.11 However, functional patency 
rates at this three month time point were lower than anticipated in both cohorts. The effect 
of anaesthetic technique on longer-term AVF functional patency remains unknown.  
 
Long-term functional patency is the ultimate goal of vascular access surgery, reducing both 
the need for further vascular access procedures and complications associated with 
tunnelled dialysis catheters (TDC). If utilising RA improved long-term outcomes it could 
therefore result in cost-savings, although this would need to be offset against the financial 
costs of a dedicated anaesthetist, anaesthetic equipment and additional time required. 
 
The purpose of this study was to analyse the clinically relevant outcome of functional AVF 
patency at one year using follow-up data from our original randomised controlled trial (RCT) 
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comparing RA to LA for AVF creation, and to evaluate the cost-effectiveness of each 
anaesthetic modality. 
 
Methods  
 
Study design and participants 
An observer-blinded RCT was performed at three university hospitals in Glasgow, UK 
(Stobhill Ambulatory Care Hospital, Western Infirmary and Queen Elizabeth University 
Hospital). The full trial design, methodology and initial (three month) outcomes have been 
published previously.11, 15 The trial protocol was approved by West of Scotland Research 
Ethics Committee 5 (12/WS/0199) (ClinicalTrials.gov Number: NCT01706354) and is 
available at https://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-14-263.   
 
A research team member approached eligible patients pre-operatively and assessed for 
eligibility. Patients were provided with study information before informed, written consent 
was obtained. The research was undertaken in accordance with the Declaration of Helsinki 
and was in keeping with the standards set by the International Conference on 
Harmonisation of Good Clinical Practice.  
 
Adults (aged 18 or older) undergoing primary radiocephalic (RCF) or brachiocephalic (BCF) 
fistula creation for the purposes of haemodialysis were eligible for inclusion. Patients were 
excluded if they: were unable or unwilling to provide informed consent; had previous 
ipsilateral attempts at AVF creation; if the radial or brachial artery was <1.8mm or cephalic 
vein was <2mm at the wrist or <3mm at the elbow on pre-operative ultrasound (without 
tourniquet); had an allergy to local anaesthetic; significant peripheral neuropathy or 
neurological disorder affecting the upper limb; infection at the anaesthetic or surgical site; 
coagulopathy; or known ipsilateral central vein stenosis (even if treated).  
 
Randomisation and masking 
Patients were randomly assigned (1:1; in blocks of eight) using a computer-generated 
allocation system to receive either RA or LA.  Study allocation was by opaque, sealed 
envelopes as produced by a member of staff independent of the research team. After 
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obtaining consent, each patient was assigned a study number and corresponding sealed 
envelope containing their study allocation. This was opened by the anaesthetist allocated to 
the theatre list. Due to the nature of the study intervention, neither the anaesthetist, 
surgeon, nor patient were blinded. The vascular access nurse performing the assessment of 
study outcomes was blinded to study allocation. 
 
Procedures: 
A detailed description of surgical and anaesthetic techniques has previously been 
published11,15 and is available at: 
https://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-14-263.In brief, a 
standard end-to-side RCF or BCF was created. Patients in the RA cohort all received an 
ultrasound guided BPB performed by one of two experienced consultant anaesthetists. The 
supraclavicular approach was chosen unless there was a contraindication, in which case an 
axillary block was undertaken. A 1:1 mixture of 0.5% L-bupivacaine and 1.5% lidocaine with 
epinephrine (1 in 200,000) was injected up to a maximum volume of 40 mL. Patients in the 
LA infiltration group received infiltration of local anaesthetic into the surgical site by the 
operating surgeon under sterile conditions using a combination of 0.5% L-bupivacaine and 
1% lidocaine injected subcutaneously immediately prior to the commencement of surgery. 
Maximum dose limits of 2 mg/kg for bupivacaine and 3 mg/kg for lidocaine (7mg/kg with 
epinephrine) were observed throughout, recognising that these effects are additive.  
 
Clinical outcomes 
The primary outcome has been reported previously.11 Secondary end points reported here 
include primary, functional and secondary patency at one year. Functional patency was 
assessed both clinically as an AVF suitable for dialysis and by ultrasound (>6mm diameter, 
<6mm from skin surface and flow rate >600ml/min16). Additional interventions (angioplasty, 
stenting and surgical revision); alternative vascular access formation and adverse events, 
including access-related complications (infection, stenosis, thrombosis), were also recorded.  
Definitions of patency are derived from Sidawy et al 17 and are outlined in the 
Supplementary Appendix.  
 
Statistical analysis 
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Results were analysed using SPSS Statistics v22 (Armonk, NY). Data were tested for 
normality. Assuming normal distribution, student’s t-test (2-tailed) was used to compare 
continuous data, and chi-squared test used to compare categorical data. Mann-Whitney U-
tests were used for non-normally distributed data. Logistic regression analysis was carried 
out to examine the interaction between AVF site (RCF/ BCF) and anaesthesia on primary and 
functional patency. P<0·05 was considered significant. Results are presented as mean (95% 
CI), median (IQR), or as a percentage of the total population and odds ratio (OR). Missing 
data were limited and assumed to be missing at random. If a data point was missing, this 
case was removed from analysis of the specific variable of interest. A “last-forward” 
approach was taken towards fistula patency in patients who died. Data were analysed on an 
intention-to-treat basis. The study was powered according to the primary outcome11 and no 
formal power calculation was performed for the secondary endpoints reported in this 
paper. 
 
Cost-comparison and cost-effectiveness analysis 
A probabilistic state-transition (Markov) model was developed, tracking the progression of 
patients with ESRD across various health states representing alternative vascular access 
modalities. Nested decision trees captured the pathways associated with the creation and 
maturation of new AVFs (Figure 1). Transition probabilities were derived from clinical data 
observed in the RCT across the one-year follow-up (Appendix table S1). 
 
All costs were estimated from the perspective of the National Health Service (NHS) and 
were converted to 2019/2020 United Kingdom Pound Sterling (GBP/£). A “bottom-up” 
approach was used to estimate costs associated with each anaesthetic technique including 
medication, equipment and staff time. Costs were derived from the British National 
Formulary (BNF);19 Personal Social Services Research Unit Costs of Health and Social Care 
2018;20 national procurement data;21 or market prices (Table S2-5) and were validated by 
clinical experts. 
 
Methodology described by Shechter et al (2017)22 was applied to derive baseline health 
utility scores for HD via different access modalities using previously published data.23,24 As 
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such, baseline utility values of 0·767 and 0·677 were assigned to health states “HD via AVF” 
and “HD via TDC” respectively (Table S6). 
 
Two sets of results were estimated. Firstly, resource utilisation data derived directly from 
the one-year follow-up of patients in the RCT was employed for cost-comparison analysis. A 
one-way sensitivity analysis was undertaken (+/-20%) to evaluate the influence of key 
factors. Secondly, the decision-analytic model described above was used to estimate the 
relative cost-effectiveness of RA compared to LA across a five-year time horizon. Costs and 
health benefits were tracked and aggregated, and incremental cost-effectiveness ratios 
(ICERs) were estimated (expressed in GBP per life-year and per quality-adjusted life-year 
(QALY)). One-way sensitivity analysis was conducted and structural uncertainty in the model 
was investigated through a series of scenario analyses. Finally, the joint parameter 
uncertainty was explored by second order Monte Carlo simulation in which a probabilistic 
distribution was fitted around each model parameter and 1,000 simulations run, repeatedly 
sampling different point estimates from these distributions and estimating alternative 
probabilistic model results. The parameters for the distributions were estimated from 
available or assumed sample statistics using the method of moments (Appendix Table S6).  
 
Role of the funding source  
The funder of the study had no role in study design, data study had no role in study design, 
data collection, data analysis, data interpretation, or writing of the writing of the report. The 
corresponding author had full access to all the data in the study and had final responsibility 
for the decision to submit for publication  
 
Results  
 
Between 6th Feb 2013, and 4th Dec 2015, 163 patients were assessed for eligibility and 126 
patients were randomly assigned to LA (n=63) or RA (n=63) (Figure 2). One patient breached 
protocol having been randomly assigned before vein mapping ultrasound (no suitable 
vessels identified). 6 patients (4 in the RA cohort and 2 in the LA cohort) died between 3 and 
12 months follow-up. Otherwise all patients completed 12-month follow-up on an intention-
to-treat basis.   
Formatted: Font color: Red
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Patient demographics have been described previously.11 The groups were similar in terms of 
age, sex, comorbidities, renal replacement modality and other baseline variables (Table 1). 
51 (40%) of 126 patients randomly assigned had a RCF created whilst the remaining 75 
(60%) had a BCF creation.  
 
Primary patency at 12 months was higher in the RA group compared to the LA group (50 
[79%] vs 37 patients [59%]; OR 2·7 [95% CI 1·6, 3·8], P=0·02) (fragility index=2). Similarly, 
functional patency at 1 year was higher in the RA cohort (43 [68%] vs 31 patients [49%]; OR 
2·1, [95% CI 1·5, 2·7] P<0.01) (fragility index=2) (Table 2).  
 
The observed benefits of RA were more marked in RCF than BCF, although formal 
interaction tests did not find demonstrate significance (Tables 3 & 4). Primary and functional 
patency rates at 12 months in RCF were 77% vs.48% (P=0.02) and 78% vs. 48% (P=0.02). No 
statistical significantly difference in functional patency at 1 year was observed in BCF (76% 
vs. 63%; P=0.25). Although not significantly different between RA and LA, overall functional 
patency of BCF was better at 12-months than 3-months (53 [69%] vs 15 patients [20%], 
P<0·01). 
 
21 revisional procedures were performed in 14 patients (Table 5). 13 patients (93%) 
successfully achieved functional patency as a result of these interventions. All revisional 
procedures were performed in BCF. No RCF required intervention. 15 of the 21 revisional 
procedures (71.4%) were performed in the RA cohort. Conversely more new AVF and 
temporary dialysis catheters (TDCs) were required in the LA cohort. Additionally, a further 
24 AVF (13 RA, 11 LA), which hadn’t achieved functional patency by 3 months, subsequently 
achieved functional patency by 12 months without additional intervention.  
 
7 patients (4 RA, 3 LA) died during the 12-month follow-up period. No death was associated 
with vascular access complications. There were no complications of anaesthetic 
administration. One patient (LA) experienced a superficial wound infection. There was one 
case of line sepsis in the LA cohort (treated with 14 days of intravenous antibiotics). Mean 
duration of hospital stay for vascular access issues was 2·5 days (range: 1-17) in 12 months. 
Formatted: Font color: Red
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High initial staff time costs in the RA cohort were offset by cost-savings of improved AVF 
maturation (fewer additional new AVF procedures and reduced TDC complications), 
delivering an overall net cost saving of £195·10 per patient at 1 year (Table 6). Full details of 
costs associated with anaesthesia, initial AVF surgery, revisions, additional accesses and 
sensitivity analyses are outlined in the Supplementary Table 3. The incremental cost was 
most sensitive to the number of alternative accesses (both AVF and TDCs) created but RA 
remained cost saving in most cases (Supplemental Figure 1).  
 
Base case results demonstrating relative cost-effectiveness of RA compared to LA over a 
five-year time horizon are summarised in Table 7. Over five years, RA resulted in a cost 
saving of approximately £2,100 per patient. In the RA cohort, patients spent relatively more 
time dialysing via AVF and derived an incremental survival and QALY benefit. The ICERs 
realised in the RA arm compared to the LA arm were approximately £10,300 per LY gained 
and £12,900 per QALY gained respectively. The robustness of base-case ICER (£/QALY) to 
variations in a wide range of model parameters and under various scenarios was 
investigated by one-way sensitivity analysis as outlined in the Supplementary Appendix 
(Figure 3, Table S7). RA was cost-effective at a £30,000/QALY threshold in all but one case: 
when the cost of dialysing via AVF was increased by 20%, the ICER picked up to 
approximately £33,000/QALY. The ICER was not higher than £30,000/QALY in any other case 
and in several cases RA dominated LA, offering a higher health benefit for a lower cost.   
 
The ongoing costs of HD are a big driver of cost-effectiveness results, with the NHS England 
cost of “HD via AVF” being paradoxically higher than “HD via TDC”. Excluding these costs 
resulted in RA dominating LA. The same effect is observed when the time-horizon of the 
analysis is reduced. The proportion of the cohort that are pre-dialysis at the start of the 
model also has a substantial impact on results, with RA being particularly cost-effective in 
patients already on dialysis at the time of initial AVF creation.  
 
Probabilistic sensitivity analysis results show a high probability of RA being cost-effective 
(89·6% at £30,000/QALY threshold and 76·3% at £20,000/QALY threshold) compared to LA 
 10 
Formatted: Position: Horizontal: Right, Relative to: Margin,
Vertical:  0 cm, Relative to: Paragraph, Wrap Around
Formatted: Right:  0.63 cm
(Figure 4). Moreover, the probability of RA to dominate LA is substantial (39·1%), whereas 
the probability of RA being dominated by LA is virtually zero (0·0%) (Figure 5). 
 
Discussion 
 
These results confirm an enduring superiority of RA over LA in achieving primary and 
functional AVF patency at 12 months and are, to our knowledge, the first randomised data 
to demonstrate an anaesthetic technique improving any long-term surgical outcome. The 
results also prove RA is cost-effective in AVF creation. Our findings serve to address 
criticisms ascribed to our original RCT,11 namely poor functional patency rates, particularly 
in BCF.  
 
The 12 month functional patency rates described here are comparable to those observed in 
other large vascular access RCTs8,24,25 and are reflective of the contemporaneous Scottish 
population.26 We hypothesised that absence of assisted maturation techniques, co-
morbidity and obesity (difficulties cannulating deep AVF, or failing to meet our functional 
patency criteria of less than 6mm from skin surface) may explain the relatively poor three 
month functional patency rates previously observed. These follow-up data suggest that, 
whilst revisional procedures were required in 14 patients, a further 24 AVF developed 
functional patency between three and 12 months without intervention, simply requiring 
additional time to mature. This supports the assertion that the early maturation period is 
key to long-term functional patency, especially amongst RCF where the functional patency 
rates at 12 months closely mirror primary patency at three months. Our data suggest that, if 
early patency (assisted by increased blood flow and vasodilatation secondary to RA) is 
established, it will ultimately be possible to achieve functional patency. This should be 
considered when determining end-points for future clinical trials. 
 
As with our previous study11, the beneficial effect of RA was more marked in the small 
vessels of RCF. Multiple interventions were needed, mainly in the RA cohort, to assist in the 
maturation of poorly developed fistulae. However, the cost of these interventions was 
offset against a need for more alternative accesses (de novo AVF and TDCs) in the LA cohort. 
Due to the relatively small sample size, cost-effectiveness analysis was not performed for 
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RCF and BCF as independent subgroups. It follows however that most of the cost savings are 
likely to be observed in patients undergoing distal fistula creation. 
 
Three smaller randomised trials all demonstrated the beneficial effects of RA in short-term 
AVF maturation although these have been considered to have a high level of bias with 
outcomes often limited to surrogate data.27, 28,29 Two recent meta-analyses also favoured 
RA14, 30 but no trial to date has studied the long-term effects of RA. Nevertheless the recent 
European Vascular Access and European Renal Best Practice guidelines recommend the use 
of RA for AVF creation1, 31. This guidance also states that RA may increase costs or delay the 
access procedure, which we have now demonstrated not to be the case. The recently 
commissioned National Institute for Health Research systematic review demonstrated a 
reduction of AVF failure by 72% with RA concluding that future studies should also include a 
cost-analysis.32 
 
The study population is largely reflective of UK practice, however it’s acknowledged that 
demographic differences exist internationally. For example in the USA there is a larger 
proportion of obese and diabetic patients (factors known to be associated with adverse AVF 
outcomes33). Similarly, in the USA assisted maturation techniques are commonly used early 
in the fistula lifespan, in part to address targets imposed by Centres for Medicare & 
Medicaid Services (CMS) targets aiming to achieve freedom from TDC by 90 days. Recent US 
analysis suggests rates of secondary AVF interventions as high as 44%34. It is therefore 
difficult to extrapolate our results to this population as only 11% of patients in this study 
had an intervention to assist maturation, none within the first 90 days. 
 
The study is limited by the lack of original quality of life (QoL) data. Baseline utility scores 
were extrapolated from other studies of health-related QoL outcomes in HD patients.23, 24 
These studies used KDQOL-SF and SF-36 to measure QoL in dialysis patients. However, to 
date, there is no validated QoL tool evaluating the impact of either dialysis modality or 
vascular access specifically. Such a tool is urgently needed for performing future cost-
effectiveness analyses of vascular access. 
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With these results we demonstrate, for the first time, net cost-savings and long-term cost-
effectiveness of RA. The cost-analysis presented reflects UK practice with health economic 
analysis performed from the perspective of the National Health Service (NHS) and UK 
Personal and Social Services. It is acknowledged that costs in other healthcare systems will 
vary with differences in both perioperative care pathways (e.g. availability of block rooms, 
different anaesthetic agents, availability of trained anaesthetists) and subsequent 
interventions to provide a functional access for dialysis (e.g. assisted maturation techniques, 
resource implications of TDC etc.) such that extrapolation of the absolute cost savings 
demonstrated within a UK setting may be limited. However results appear robust 
throughout extensive sensitivity and scenario analyses and our model could be adapted to 
reflect variations in healthcare in an international setting. 
 
Even within our model, the distribution of cost-savings is complex and controversial. The 
national tariff in England and Wales incentivises AVF use by providing cost-savings to 
individual dialysis centres for “HD via AVF”. However, the overall net costs to the health 
service, society at large, and therefore to cost-effectiveness analyses, are higher than “HD 
via TDC”. The “costs” of care are not actually higher with AVF, rather the commissioner-to-
institution reimbursement is. The decision whether or not to include ongoing HD costs in 
cost-effectiveness analysis is therefore a matter of debate,35 given that the more clinically 
effective an intervention is, the more it will disproportionately impact the costs in favour of 
the less effective comparator. Similarly the higher overall survival in the RA arm translates 
to the accruing of relatively higher ongoing costs of HD. These idiosyncrasies lead to 
underestimating the true cost-effectiveness benefit derived from improving access 
outcomes.  The absence of dialysis-associated costs (such as the need for alternative 
accesses) limits cost-savings in pre-dialysis patients. These patients should be considered as 
a separate cohort for future studies of cost-effectiveness. Future studies of cost-
effectiveness in vascular access should focus on measurement of long-term overall 
healthcare costs rather than basic maintenance haemodialysis costs and reimbursement 
fees.  
 
In conclusion, this is the first randomised study of any perioperative intervention to 
demonstrate enduring improvement in AVF patency at 12 months. We have presented 
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mechanistic explanation11, clinical benefit and evidence of cost-effectiveness. Moreover, 
this trial demonstrates the value of a multidisciplinary approach to vascular access with 
motivated surgeons, anaesthetists, nephrologists, access nurses and health economists all 
contributing. On this basis, we reaffirm our assertion that RA should be used for all de novo 
AVF creation. 
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Tables 
 
Table 1: Baseline characteristics. Data are presented as n (%) or mean +/- S.D. unless otherwise stated. IHD= 
ischaemic heart disease; CVA= cerebrovascular accident; HD= haemodialysis; PD= peritoneal dialysis; IQR= 
interquartile range; Pre-D= pre-dialysis; RA=regional anaesthesia; LA=local anaesthetic 
*median (IQR) 
 
 Overall patient 
population 
(n=126) 
RA 
(n=63) 
LA 
(n=63) 
Age (years) 60.8+/-14·8 59·5+/-15·3 62·1+/-14·3 
Sex (% male) 79 (62·7%) 40 (63·5%) 39 (61·9%) 
Primary renal disease 
Diabetes 
Multisystem 
Interstitial 
Glomerulonephritis 
Unknown 
 
21 (16·7%) 
16 (12·7%) 
41 (32·5%) 
24 (19·0%) 
24 (19·0%) 
 
10 (15·9%) 
9 (14·3%) 
16 (25·4%) 
15 (23·8%) 
13 (20·6%) 
 
11 (17·5%) 
7 (11·1%) 
25 (39·7%) 
9 (14·2%) 
11 (17·5%) 
Co-morbidities 
Diabetes 
IHD 
CVA 
Hypertension 
Obesity (BMI <30) 
 
34 (27·0%) 
48 (38·1%) 
9 (7·1%) 
93 (73·8%) 
41 (32·5%) 
 
17 (27·0%) 
22 (34·9%) 
3 (4·8%) 
40 (68·3%) 
22 (34·9%) 
 
17 (27·0%) 
26 (41·2%) 
6 (9·5%) 
53 (84·1%) 
19 (30·2%) 
Medications 
Antihypertensives (number)* 
Aspirin 
Clopidogrel 
Statin 
 
2 (1,4) 
85 (67·4%) 
29 (23·0%) 
73 (57·9%) 
 
2 (1,4) 
42 (66·7%) 
13 (20·6%) 
38 (60·3%) 
 
2 (1,4) 
43 (68·3%) 
16 (25·4%) 
35 (55·6%) 
RRT modality at time of 
randomization 
HD 
Pre-dialysis 
 
 
63 (50%) 
63 (50%) 
 
 
30 (47·6%) 
33 (52·4%) 
 
 
33 (52·4%) 
30 (47·6%) 
Site of AVF 
RCF 
BCF 
 
51 (40·5%) 
75 (59·5%) 
 
26 (41·2%) 
37 (58·7%) 
 
25 (39·7%) 
38 (60·3%) 
Surgeon 
1 
2 
3 
4 
5 
Others 
 
35 (27·8%) 
23 (18·3%) 
16 (12·7%) 
16 (12·7%) 
14 (11·1%) 
22 (17 ·4%) 
 
16 (25·4%) 
13 (20·6%) 
8 (12·7%) 
8 (12·7%) 
8 (12·7%) 
10 (15·9%) 
 
19 (30·2%) 
10 (15·9%) 
8 (12·7%) 
8 (12·7%) 
6 (9·5%) 
12 (19·0%) 
Anaesthetist 
1 
2 
  
36 (57·1%) 
27(42·9%) 
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Table 2: Patency rates of AVF (primary, secondary and functional patencies at 3 and 12 months). Numbers 
presented are total number of patients (percentage [95% CI]). AVF=arteriovenous fistula; BCF=brachiocephalic 
fistula; RCF=radiocephalic fistula; RA=regional anaesthesia; LA=local anaesthetic 
 Overall patient 
population (n=126) 
RA 
(n=63) 
LA 
(n=63) 
P-value 
ALL AVF 
Primary patency at 3 months 
 
Functional patency at 3 months 
 
Secondary patency at 3 months 
 
 
Primary patency at 1 year 
 
Functional patency at 1 year 
 
Secondary patency at 1 year 
 
 
92 (73%) 
[65%, 80%] 
44 (35%) 
[27%, 44%] 
92 (73%) 
[65%, 80%] 
 
87 (69%) 
[64%,76%] 
74 (59%) 
[62%, 72%] 
71 (56%) 
[50%, 62%] 
 
53 (84%) 
[73%,91%] 
26 (41%) 
[30%, 54%] 
53 (84%) 
[73%,91%] 
   
50 (79%) 
[72%, 86%] 
43 (68%) 
[7%, 82%} 
40 (62%) 
[55%, 69%] 
 
39 (62%) 
[49%,72%] 
18 (29%) 
[19%, 41%] 
39 (62%) 
[49%,72%] 
 
37 (59%) 
[54%, 63%] 
31 (49%) 
[52%, 62%] 
31 (49%) 
[44%, 55%] 
 
<0·01 
 
0·15 
 
<0·01 
 
0·02 
 
<0.01 
 
0·04 
RCF (n=51) 
Primary patency at 3 months 
 
Functional patency at 3 months 
 
Secondary patency at 3 months 
 
 
Primary patency at 1 year 
 
Functional patency at 1 year 
 
Secondary patency at 1 year 
 
 
32 (63%) 
[50%, 76%] 
29 (57%) 
[44%,71%] 
32 (63%) 
[50%, 76%] 
 
32 (63%) 
[50%, 76%] 
33 (65%) 
[49%, 75%} 
31 (61%) 
[49%, 73%] 
 
20 (77%) 
[65%, 87%] 
19 (73%) 
[56%, 89%] 
20 (77%) 
[65%, 87%] 
 
20 (77%) 
[65%, 87%] 
21(78%) 
[66%, 88%] 
19 (73%) 
[65%, 81%] 
 
12 (48%) 
[35%, 61%] 
10 (40%) 
[23%, 59%] 
12 (48%) 
[35%, 61%] 
 
12 (48%) 
[35%, 61%] 
12 (48%) 
[35%, 61%] 
12 (48%) 
[35%, 61%] 
 
0·03 
 
0·02 
 
0·03 
 
0·02 
 
0·02 
 
0·04 
BCF (n=75) 
Primary patency at 3 months 
 
Functional patency at 3 months 
 
Secondary patency at 3 months 
 
 
Primary patency at 1 year 
 
Functional patency at 1 year 
 
Secondary patency at 1 year 
 
60 (80%) 
[66%,85%] 
15 (20%) 
[12%, 29%] 
60 (80%) 
[66%,85%] 
 
55 (73%) 
[67%, 81%] 
53 (69%) 
[63%, 75%] 
41(55%) 
[51%, 58%] 
 
33 (89%) 
[72%,95%] 
7 (19%) 
[9%, 34%] 
33 (89%) 
[72%,95%] 
 
30 (81%) 
[72%, 90%] 
29 (76%) 
[69%, 83%] 
22 (56%) 
[51%, 61%] 
 
27 (71%) 
[55%, 73%] 
8 (21%) 
[11%, 37%] 
27 (71%) 
[55%, 73%] 
 
25 (68%) 
[60%, 76%] 
24 (63%) 
[56%, 71%] 
19 (50%) 
[44%, 56%] 
 
0·05 
 
0·95 
 
0·05 
 
0·36 
 
0·25 
 
0.46 
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Table 3: Logistic regression analysis examining the interaction between anaesthetic type and AVF site on 
primary patency at 12 months. RCF=radiocephalic; BCF=brachiocephalic; RA=regional anaesthesia; LA= local 
anaesthesia. *Reference: RCF; ** Reference RA 
 
 Beta Standard 
error 
Wald 
statistic 
P-value Exp (B) 95% CI 
Intercept 0.70 0.68 1.04 0.31   
AVF site (RCF/ 
BCF)* 
-0.66 0.40 2.70 0.10 0.52 0.23, 1.14 
Anaesthetic type 
(RA/ LA)** 
-1.04 0.41 6.41 0.01 0.35 0.16, 0.80 
 
 
Table 4: Logistic regression analysis examining the interaction between anaesthetic type and AVF site on 
functional patency at 12 months. RCF=radiocephalic; BCF=brachiocephalic; RA=regional anaesthesia; LA= local 
anaesthesia.*Reference: RCF; ** Reference RA 
 
 Beta Standard 
error 
Wald 
statistic 
P-value Exp (B) 95% CI 
Intercept 0.40 0.69 0.35 0.55   
AVF site (RCF/ 
BCF)* 
-0.43 0.40 1.2 0.28 0.65 0.30, 1.40 
Anaesthetic type 
(RA/ LA)** 
-1.08 0.40 7.1 0.007 0.34 0.50, 0.75 
 
Table 5: Number of additional procedures first year. *denotes an intervention for failure to mature/ assisted 
functional patency. Number of patients is reflected in brackets () 
 RA LA 
Superficialisation/ transposition 4 (4) 3 (2) 
Collateral/ branch ligation 2 (2)  
Superficialisation and collateral 
ligation 
 1 (1) 
Revision of arterial inflow and 
collateral ligation 
1 (1)  
Distal revascularisation and 
interval ligation 
1 (1)  
Proximalisation 1 (1)  
Radiological declot and angioplasty 1 (1)  
Angioplasty (outflow) 4 (3) 1 (1) 
Angioplasty and central venous 
stenting  
2 (2)  
New AVF 20 (18) 33 (27) 
AVG 3 (3) 3 (3) 
Tunnelled dialysis catheter (TDC) 21 (18) 29 (20) 
Temporary dialysis catheter 4 (3) 4 (4) 
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Table 6: Breakdown of costs per patient in the RA and LA arms at 1-year follow-up 
 LA RA 
Anaesthesia component £2·61 £87·43 
Medicines  £2·44   £13·33  
Equipment/consumables  £0·17   £21·51  
Staff time negligible  £52·60 
AVF surgery £2,095·00 £2,095·00 
Revision procedures £97·37 £343·84 
Additional AVFs £1,097·38 £665·08 
TDC insertion £341·10 £247·00 
Total cost £3,633·45 £3,438·35 
Incremental cost  -£195·10 
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Table 7: Base case results cost-effectiveness analysis (per patient) 
 LA RA Incremental 
Costs    
Anaesthesia £6·24 £140·99 £134·75 
AVF surgery £5,011·13 £3,378·34 -£1,632·79 
Revisions £46·13 £167·03 £120·89 
TDC costs £729·86 £397·14 -£332·72 
Infection costs £4,485·06 £3,021·97 -£1,463·09 
HD costs £75,833·72 £81,111·14 £5,277·42 
Total £86,112·14 £88,216·60 £2,104·46 
    
Health benefits    
HD via AVF (months) 29·3 38·1 8·7 
HD via TDC (months) 11·0 4·7 -6·3 
Infection episodes 0·65 0·43 -0.22 
Life-years (LYs) 3·842 4·047 0·205 
QALYs 2·673 2·836 0·163 
    
ICER (£/LY)   £10,256·82 
ICER (£/QALY)   £12,898·87 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
